Literature DB >> 26159481

A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.

Ziyad F Al-Rashid1, Richard P Hsung2.   

Abstract

A computational docking study of a series of de novo structural analogs of the highly potent, non-nitrogen containing, acetylcholinesterase inhibitor (+)-arisugacin A is presented. In direct comparison to the recently reported X-ray single-crystal structure of (+)-territrem B bound hAChE, the modeling suggests that there is a unique conformational preference for the E-ring that is responsible for the superior inhibitory activity of (+)-arisugacin A against hAChE relative to (+)-territrem B, and that substitutions on the E-ring also play an important role in the protein-ligand interaction. Published by Elsevier Ltd.

Entities:  

Keywords:  (+)-Arisugacin A; Acetylcholinesterase; Alzheimer’s disease; Computational modeling; E-ring conformation; E-ring substitutions; Territrems

Mesh:

Substances:

Year:  2015        PMID: 26159481      PMCID: PMC4670034          DOI: 10.1016/j.bmcl.2015.06.047

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  49 in total

1.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.

Authors:  G Kryger; I Silman; J L Sussman
Journal:  Structure       Date:  1999-03-15       Impact factor: 5.006

2.  Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils.

Authors:  A Alvarez; C Opazo; R Alarcón; J Garrido; N C Inestrosa
Journal:  J Mol Biol       Date:  1997-09-26       Impact factor: 5.469

Review 3.  Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease.

Authors:  D L Bai; X C Tang; X C He
Journal:  Curr Med Chem       Date:  2000-03       Impact factor: 4.530

Review 4.  Cholinesterases: new roles in brain function and in Alzheimer's disease.

Authors:  Ezio Giacobini
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 5.  The cholinergic hypothesis--ten years on.

Authors:  E K Perry
Journal:  Br Med Bull       Date:  1986-01       Impact factor: 4.291

6.  Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.

Authors:  Pelayo Camps; Xavier Formosa; Carles Galdeano; Diego Muñoz-Torrero; Lorena Ramírez; Elena Gómez; Nicolás Isambert; Rodolfo Lavilla; Albert Badia; M Victòria Clos; Manuela Bartolini; Francesca Mancini; Vincenza Andrisano; Mariana P Arce; M Isabel Rodríguez-Franco; Oscar Huertas; Thomai Dafni; F Javier Luque
Journal:  J Med Chem       Date:  2009-09-10       Impact factor: 7.446

Review 7.  Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

Authors:  Ana Castro; Ana Martinez
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 8.  Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

Authors:  D Muñoz-Torrero
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 9.  Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

Authors:  Daniel M Skovronsky; Virginia M-Y Lee; John Q Trojanowski
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

Review 10.  Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics.

Authors:  Maurizio Recanatini; Piero Valenti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  3 in total

Review 1.  A Comprehensive Review of Cholinesterase Modeling and Simulation.

Authors:  Danna De Boer; Nguyet Nguyen; Jia Mao; Jessica Moore; Eric J Sorin
Journal:  Biomolecules       Date:  2021-04-15

2.  Synthesis of novel benzothiazole derivatives and investigation of their enzyme inhibitory effects against Alzheimer's disease.

Authors:  Şevval Karaca; Derya Osmaniye; Begum Nurpelin Sağlık; Serkan Levent; Sinem Ilgın; Yusuf Özkay; Ahmet Çağrı Karaburun; Zafer Asım Kaplancıklı; Nalan Gundogdu-Karaburun
Journal:  RSC Adv       Date:  2022-08-19       Impact factor: 4.036

3.  Design, Synthesis, and Structure-Activity Relationships of Thiazole Analogs as Anticholinesterase Agents for Alzheimer's Disease.

Authors:  Begüm Nurpelin Sağlık; Derya Osmaniye; Ulviye Acar Çevik; Serkan Levent; Betül Kaya Çavuşoğlu; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2020-09-20       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.